BC patients with LVD due to anti-HER2 were more commonly treated with pertuzumab (46 vs. 20%, p = 0.04), but there was no association with anthracyclines therapy (62 vs. 55%, p = 0.77). This evidence concerns the gene ERBB2 and breast cancer.